• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

新型皮质类固醇布地奈德每日两次给药与二丙酸倍氯米松每日四次给药治疗慢性哮喘的比较。

Comparison of twice daily administration of a new corticosteroid budesonide with beclomethasone dipropionate four times daily in the treatment of chronic asthma.

作者信息

Willey R F, Godden D J, Carmichael J, Preston P, Frame M, Crompton G K

出版信息

Br J Dis Chest. 1982 Jan;76(1):61-8.

PMID:7037035
Abstract

The efficacy and side-effects of a new corticosteroid aerosol, budesonide and beclomethasone dipropionate were assessed in 30 patients with chronic asthma in a double-blind cross-over study. Budesonide was administered, 200 micrograms twice daily, from a conventional pressurized aerosol with a tube spacer extension attached and beclomethasone was given via a conventional inhaler in the recommended four times daily dose of 100 micrograms, each treatment being administered for one month. No clinically significant differences were found between the two treatments and no significant side-effects were observed.

摘要

在一项双盲交叉研究中，对30例慢性哮喘患者评估了一种新型皮质类固醇气雾剂布地奈德和丙酸倍氯米松的疗效及副作用。布地奈德通过连接有延长管的传统加压气雾剂给药，每日两次，每次200微克；丙酸倍氯米松通过传统吸入器给药，推荐剂量为每日四次，每次100微克。每种治疗均持续一个月。两种治疗之间未发现临床显著差异，也未观察到明显的副作用。

相似文献

1
Comparison of twice daily administration of a new corticosteroid budesonide with beclomethasone dipropionate four times daily in the treatment of chronic asthma.新型皮质类固醇布地奈德每日两次给药与二丙酸倍氯米松每日四次给药治疗慢性哮喘的比较。
Br J Dis Chest. 1982 Jan;76(1):61-8.
2
Twice daily inhalation of a new corticosteroid, budesonide, in the treatment of chronic asthma.每日两次吸入新型皮质类固醇布地奈德治疗慢性哮喘。
Eur J Respir Dis Suppl. 1982;122:138-42.
3
Equally efficacious asthma management with budesonide 800 micrograms administered by Turbuhaler or with beclomethasone dipropionate > or = 1500 micrograms given through a pressurized metered-dose inhaler with spacer. The French Budesonide Trial Group.使用都保装置吸入800微克布地奈德与使用带储雾罐的压力定量气雾剂吸入≥1500微克二丙酸倍氯米松在哮喘管理方面疗效相当。法国布地奈德试验组。
Adv Ther. 1996 Jan-Feb;13(1):38-50.
4
[High dose inhaled steroids in the treatment of bronchial asthma. A comparison of the effects of budesonide and beclomethasone dipropionate on pulmonary function, symptoms, bronchial reactivity and adrenocortical function].[高剂量吸入性类固醇治疗支气管哮喘。布地奈德和二丙酸倍氯米松对肺功能、症状、支气管反应性及肾上腺皮质功能影响的比较]
Ugeskr Laeger. 1993 Jul 12;155(28):2197-202.
5
A single blinded randomised trial to compare the efficacy and safety of once daily budesonide (400microg) administered by turbuhaler with beclomethasone dipropionate (400microg) given twice daily through a metered-dose inhaler in patients with mild to moderate asthma.一项单盲随机试验，比较在轻度至中度哮喘患者中，使用都保每日一次吸入布地奈德（400微克）与使用定量气雾剂每日两次吸入二丙酸倍氯米松（400微克）的疗效和安全性。
Afr J Med Med Sci. 2004 Jun;33(2):155-60.
6
Hay fever treatment with budesonide and beclomethasone dipropionate twice daily - a clinical comparison.
Rhinology. 1983 Dec;21(4):335-40.
7
Asthma treatment with a new corticosteroid aerosol, budesonide, administered twice daily by spacer inhaler.使用一种新型皮质类固醇气雾剂布地奈德进行哮喘治疗，通过储雾罐吸入器每日给药两次。
Arch Dis Child. 1982 Nov;57(11):864-6. doi: 10.1136/adc.57.11.864.
8
Budesonide inhaled via Turbuhaler: a more effective treatment for asthma than beclomethasone dipropionate via Rotahaler.通过都保吸入布地奈德：一种比通过准纳器吸入二丙酸倍氯米松更有效的哮喘治疗方法。
Ann Allergy Asthma Immunol. 1995 Aug;75(2):107-11.
9
Effect of inhaled budesonide on severe steroid-dependent asthma.
Eur J Respir Dis. 1987 Apr;70(4):239-44.
10
A clinical comparison of intranasal budesonide with beclomethasone dipropionate for perennial non-allergic rhinitis: a 12 month study.
Br J Clin Pract. 1996 Oct-Nov;50(7):363-6.

引用本文的文献

1
Differences in the effectiveness of single, dual, and triple inhaled corticosteroid therapy for reducing future risk of severe asthma exacerbation: A systematic review and network meta-analysis.单药、双联和三联吸入性糖皮质激素疗法在降低重度哮喘加重未来风险方面的疗效差异：一项系统评价和网状Meta分析。
Heliyon. 2024 May 16;10(12):e31186. doi: 10.1016/j.heliyon.2024.e31186. eCollection 2024 Jun 30.
2
Inhaled corticosteroids in childhood asthma: the story continues.儿童哮喘吸入性皮质类固醇：故事仍在继续。
Eur J Pediatr. 2011 Jun;170(6):709-18. doi: 10.1007/s00431-010-1319-z. Epub 2010 Oct 8.
3
North of England evidence based guidelines development project: summary version of evidence based guideline for the primary care management in adults.
英格兰北部循证指南制定项目：成人初级保健管理循证指南概要版
BMJ. 1996 Mar 23;312(7033):762-6. doi: 10.1136/bmj.312.7033.762.
4
Long term clinical comparison of single versus twice daily administration of inhaled budesonide in moderate asthma.中度哮喘患者中吸入布地奈德每日一次与每日两次给药的长期临床比较
Thorax. 1995 Dec;50(12):1270-3. doi: 10.1136/thx.50.12.1270.
5
Comparison of fluticasone propionate with beclomethasone dipropionate in moderate to severe asthma treated for one year. International Study Group.丙酸氟替卡松与二丙酸倍氯米松治疗中重度哮喘一年的比较。国际研究小组。
Thorax. 1993 Aug;48(8):817-23. doi: 10.1136/thx.48.8.817.
6
Sample sizes for comparative inhaled corticosteroid trials with emphasis on showing therapeutic equivalence.重点在于显示治疗等效性的吸入性糖皮质激素对比试验的样本量。
Eur J Clin Pharmacol. 1995;48(3-4):179-84. doi: 10.1007/BF00198295.
7
Asthma treatment with a new corticosteroid aerosol, budesonide, administered twice daily by spacer inhaler.使用一种新型皮质类固醇气雾剂布地奈德进行哮喘治疗，通过储雾罐吸入器每日给药两次。
Arch Dis Child. 1982 Nov;57(11):864-6. doi: 10.1136/adc.57.11.864.
8
Budesonide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy in asthma and rhinitis.布地奈德。对其在哮喘和鼻炎中的药效学特性及治疗效果的初步综述。
Drugs. 1984 Dec;28(6):485-518. doi: 10.2165/00003495-198428060-00001.
9
Failure of once daily inhaled corticosteroid treatment to control chronic asthma.每日一次吸入糖皮质激素治疗未能控制慢性哮喘。
Thorax. 1984 Dec;39(12):933-4. doi: 10.1136/thx.39.12.933.
10
Beclomethasone dipropionate. A reappraisal of its pharmacodynamic properties and therapeutic efficacy after a decade of use in asthma and rhinitis.二丙酸倍氯米松。在用于哮喘和鼻炎十年后对其药效学特性和治疗效果的重新评估。
Drugs. 1984 Aug;28(2):99-126. doi: 10.2165/00003495-198428020-00002.